Autosomal recessive osteopetrosis (OP) is a disease characterized by osteoclast dysfunction, leading to multisystem morbidity and death of most affected children. Hematopoietic stem cell transplantation (HSCT) is the treatment of choice for OP, but this patient population is particularly prone to post-transplant complications and death after myeloablative conditioning. To determine the potential of achieving improved overall outcomes in these patients by decreasing pre-transplant mortality, we investigated engraftment and survival following a reduced intensity regimen including busulfan, fludarabine and total lymphoid irradiation. We report outcomes in 11 patients. All six patients who received a bone marrow or peripheral stem cell graft engrafted with 475% donor chimerism. In contrast, all five recipients of unrelated cord blood as a stem cell source for a first graft failed to demonstrate donor hematopoietic chimerism. The day 100 and 6-month mortality was low at 9%. One year after HSCT, six of 11 patients (55%) were surviving. Our data suggest that this regimen results in low peri-transplant mortality without compromising engraftment when a marrow or peripheral stem cell graft is used. An umbilical cord blood graft, however, should be used with caution for patients with OP when this or a similar reduced intensity regimen is used.
Introduction
Autosomal recessive osteopetrosis, also termed 'infantile' or 'malignant' osteopetrosis (OP), arises from a heterogeneous group of mutations resulting in abnormal osteoclast function. 1, 2 More than half of the children with severe OP have mutations in osteoclast-specific H þ -ATPase proton pump A3 subunit (TCIRG1), whereas the second most common genotype is due to recessive mutations in the chloride channel gene, ClCN7. [3] [4] [5] Other involved genes include isolated reports of rare mutations in the gray lethal gene, 6 as well as abnormalities in the carbonic anhydrase II gene. 7 The deposition of bone by osteoblasts without resorption by osteoclasts results in marked increase in bone density and causes encroachment of bone marrow space resulting in progressive marrow failure and compensatory extramedullary hematopoiesis. 8, 9 Compression of cranial nerves leads to neurological deficits, particularly blindness, that may occur early in life. A majority of the children with autosomal recessive OP die in the first decade of life owing to bleeding or infection. 10, 11 A variety of medical interventions have been attempted in OP, including high-dose calcitriol, parathormone, steroids, interferon and macrophage colony-stimulating factor, but efficacy has been variable and, at best, transient. [12] [13] [14] [15] At present, hematopoietic stem cell transplantation (HSCT) remains the only approach with the possibility of definitive and long-term benefits. 16, 17 Successful allogeneic HSCT leads to engraftment of donor-derived functioning osteoclasts, resulting in bony remodeling and establishment of normal hematopoiesis. 18 Also, if the HSCT is performed before significant optic nerve compression, visual compromise may be prevented.
However, in children with osteopetrosis, HSCT has been associated with a high incidence of adverse outcomes, especially when alternative stem cell sources are utilized. [19] [20] [21] [22] Common reasons for failure have been difficulty in achieving sustained donor engraftment and early transplant mortality from events such as sepsis. OP patients are also prone to severe pulmonary hypertension in the early posttransplant period, with a high risk of respiratory failure following HSCT. 23 In an attempt to decrease peri-transplant mortality and poor outcomes with standard transplant regimens, we developed a reduced intensity transplant regimen for patients with autosomal recessive OP. We report outcomes in 11 patients with OP using a reduced intensity preparative regimen containing busulfan, fludarabine, antithymocyte globulin and total lymphoid irradiation.
Patients and methods
Between 2000 and 2003, 11 patients received allogeneic HSCT with reduced intensity conditioning for OP at two institutions; eight patients at one institution and three patients in the second center. Follow-up is reported through January 2006. For nine patients, this regimen was used as preparatory therapy for the initial transplant, and in two cases it was used for a second HSCT, following prior graft failure. Transplant protocols were approved by respective institutional review boards, and informed consent was obtained in all cases before the procedure. The preparative regimen consisted of busulfan 2 mg/kg (1.6 mg/ kg for patients over 4 years of age) intravenously (i.v.) twice daily for two consecutive days (days À8 and À7; total dose 8 mg/kg), fludarabine 35 mg/m 2 once daily i.v. for five consecutive days (days À6 to À2; total dose 175 mg/m 2 ), antithymocyte globulin 30 mg/kg once daily i.v. for five consecutive days (days À6 to À2; total dose 150 mg/kg; in one patient horse antithymocyte globulin, ATGAM, was substituted for rabbit antithymocyte globulin, Thymoglobulin, 3 mg/kg once daily i.v. for the same five consecutive days), along with total lymphoid and abdominal irradiation of 500 cGy delivered as a single fraction on day À1. After concerns were raised regarding possible inferior engraftment associated with unrelated umbilical cord blood grafts, the preparative regimen was modified in two patients. One child (patient 5, Table 1 ) received a total of 16 mg/kg of busulfan. In another patient (patient 7) 60 mg/ kg of cyclophosphamide i.v. as a single dose was also administered in addition to the above-mentioned preparative regimen.
Graft-versus-host disease (GvHD) prophylaxis consisted of cyclosporine and mycophenolate mofetil. All but one patient received an unmanipulated stem cell graft from an unrelated donor. Hematopoietic chimerism was assessed on peripheral blood leukocyte DNA by competitive PCR analysis of variable tandem repeat regions. 24 
Results
Patient's age, donor graft characteristics and transplant outcomes are summarized in the Table 1 . The median age at HSCT was 1 year (range, 0.5-24 years). The indication for second HSCT was loss of donor chimerism and there /l, first of 3 days (without growth factor). Platelet recovery: untransfused platelet count of more than 50 Â 10 9 /l, first of 7 days.
was an interval of 2.4 years (patient 10) and 7 months (patient 11), respectively, between their first and second transplants. Donor engraftment (defined as donor chimerism of more than 75%) was observed in six patients (Table 1 ). All five patients who received bone marrow or peripheral blood stem cell (PBSC) donor grafts achieved donor engraftment. Four of these five patients were the initial transplants. One patient (patient 8) developed autologous reconstitution with maximum donor engraftment of 83% on day 16, which decreased to 38% by day 90 after transplant. On day 97, this patient received a second stem cell infusion using an aliquot of previously stored PBSC from the same donor (cell dose
Five of nine patients (55%) and one of two patients survived the first and second HSCT, respectively. The causes of death included severe GvHD with pulmonary and intracranial hemorrhage (patient 1), sudden respiratory arrest at home 2.5 years after autologous reconstitution (patient 2), multiorgan failure 50 days after HSCT (patient 5), sepsis (patient 6) and refractory autoimmune hemolytic anemia 7 months after HSCT (patient 10).
Other significant transplant-related morbidity consisted of the following: bacteremia in three patients; successfully treated post-transplant lymphoproliferative disease in one patient (patient 8) and severe autoimmune hemolytic anemia in two patients after transplant. Although fatal in one case (patient 10, as noted above), in the other patient it resolved completely with corticosteroid therapy.
Unexpectedly, in the group undergoing the first HSCT, all five patients who received an unrelated umbilical cord blood graft failed to achieve donor engraftment, including a patient who received a double cord blood transplant with a cumulative cell dose of 3.5 Â 10 8 nucleated cells/kg (patient 9, Table 1 ). He showed donor engraftment of 29% on days 29 and 35, which decreased to 0% (with full autologous recovery) on day 54 after transplant and has not recovered despite of a rapid wean off immunosuppression (cyclosporine and mycophenolate mofetil).
Patient 7 is alive with no evidence of donor engraftment. He is blind and quite active, but requires weekly blood transfusions.
Discussion
In this series, we were successful in achieving low morbidity and mortality with transplantation. In addition, all patients who received a bone marrow or PBSC graft achieved donor engraftment. In contrast, all recipients of unrelated cord blood as a stem cell source for a first graft failed to demonstrate donor hematopoietic chimerism. Patients with autosomal recessive OP are at high risk of life-threatening complications in the peri-transplant period. Also, the inability to achieve sustained donor graft is 30-40% when a source other than a matched-related donor is utilized. [18] [19] [20] [21] [22] [23] For example, in the data reported by the European Bone Marrow Transplant Group using primarily myeloablative preparative regimens, survival with osteoclast function was 73-79% following a genotypically HLA-identical transplant; however, with a mismatched related or matched unrelated donor, disease-free survival varied from 38 to 43%. 19, 20 The use of an umbilical cord blood graft in the setting of a first transplant was clearly not adequate to achieve engraftment for patients with OP using this reduced intensity regimen. In two of these five patients who received cord blood stem cells, modifications were made to increase the 'intensity' of the preparative regimen (patients 5 and 7, details in 'Patients and methods' section) owing to concerns regarding graft failure in previous umbilical cord blood recipients. Despite these modifications, donor engraftment did not occur. Hence, in another patient who lacked a suitable registry marrow donor, a double umbilical cord blood graft was utilized in an attempt to increase the probability of engraftment (patient 9). The rationale was recent data showing improved engraftment results in adults with hematological malignancy utilizing unrelated double umbilical cord blood grafts. 25 However, this patient also failed to achieve donor engraftment despite a combined cell dose of 3.5 Â 10 8 nucleated cells/ kg (5.3 Â 10 6 CD34 þ cells/kg). In contrast, in a patient undergoing a second transplant procedure utilizing an unrelated umbilical cord blood graft, complete donor chimerism was achieved. Although this experience represents a single patient, it is possible that engraftment was achieved owing to prior bony remodeling following engraftment with the first transplant, as this graft slowly failed over period of more than two years. The prior transient osteoclast engraftment with partial recanalization of the marrow cavity following the first transplant 26 may have provided a greater opportunity for donor cells to localize to the marrow.
The reasons why cord blood stem cells appear inferior as a graft source for the other OP patients using this preparative regimen is unclear. There are only few reported cases of successful cord blood transplantation in OP, [26] [27] [28] [29] and variations in genotype, phenotype treatment before cord blood infusion and stem cell dose make any conclusions difficult. In addition, negative outcomes are likely to be under-reported.
Both bone resorbing osteoclasts (derived from hematopoietic stem cell) and supportive mesenchymal stromal cells (derived from non-hematopoietic mesenchymal stem cells) may play a role in successful donor engraftment and bone resorption. 30 It has previously been demonstrated that neutrophil and platelet recovery is slower in cord blood recipients in comparison with those receiving unrelated donor grafts in other diseases, presumably because the lower stem cell dose per graft in cord blood, relative to bone marrow or peripheral blood graft, is not completely offset by higher growth and differentiation potential of more immature cord blood hematopoietic stem cells. 31 In regards to the role of non-hematopoietic stem cells in OP, the bone marrow environment is abnormal and Reduced intensity conditioning for osteopetrosis J Tolar et al insufficient to support hematopoiesis. Even though the stromal cells are rare in any graft (procured by bone marrow, peripheral blood or cord blood collection), importantly, when compared to bone marrow, many fewer mesenchymal stem cells can be isolated from umbilical cord blood. [32] [33] [34] [35] This, in turn, can contribute to an environment already less permissive for donor engraftment, as a result of marked reduction of medullary space filled with bone. In fact, it is assumed that hematopoietic engraftment occurs initially in the liver and spleen. The bone marrow space is created over time and hematopoiesis then localizes to the bone marrow cavity. Assuming this is the case, it is possible that in a setting of a reduced intensity regimen, a cord blood graft has relative disadvantage in achieving such sequential engraftment required for OP patients.
Prior experience with HSCT in OP suggests that this patient population is particularly prone to early posttransplant complications and death. [18] [19] [20] [21] [22] In this series, the day 100 and 6-month mortality was low at 9% for both timepoints. One year after HSCT, six of 11 patients (55%) were surviving. This is encouraging, as poor outcomes were observed previously in this group of patients who are almost exclusively treated with grafts from alternative donors.
Survival with donor engraftment in our series was 36% (four of 11 patients). However, of those transplanted with marrow or peripheral blood stem cells, 80% (four out of five) are surviving with a functioning graft. Our previously published data using myeloablative preparative regimens for HSCT in OP showed similar survival to the experience of others, as the proportion of patients surviving with donor engraftment was 30% (three of 10 patients). 17 Since then, two more patients underwent unrelated donor HSCT using myeloablative transplant at University of Minnesota (unpublished data); both showed donor engraftment, but both died within 100 days of transplant.
Thus, in comparison to our previous data and the experience of others with myeloablative transplants, [17] [18] [19] [20] [21] [22] it appears that transplant-related mortality is reduced with this reduced intensity regimen. In addition, our data suggest that this regimen does not compromise engraftment when a marrow or PBCS graft is used. Based on our data, however, we would hesitate to utilize umbilical cord blood grafts for a first HSCT using this reduced intensity regimen.
